CORONA Remedies Q2FY27 Revenue Surges 22% to ₹441 Cr, Outpacing IPM Growth
CORONA Remedies reported Q2FY27 revenue of ₹441.2 crore, a 22.2% YoY increase, outpacing IPM growth by 1.9x. EBITDA rose 22.3% to ₹96.0 crore, and PAT increased 15.3% to ₹60.3 crore. The company received ANVISA GMP certification for its Ahmedabad facility.
The substantial revenue growth, outperformance against market benchmarks, and international regulatory certification are significant positive developments that are likely to impact investor sentiment and the company's market position.
The company reported strong revenue growth, outperforming market growth, and received a significant international certification, indicating positive business performance and expansion.
CORONA Remedies Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company reported a significant year-on-year revenue growth of 22.2% for Q2FY27, reaching ₹441.2 crore, compared to ₹361.1 crore in Q2FY26. For the half-year ended H1FY27, revenue grew by 22.0% to ₹863.6 crore from ₹707.7 crore in H1FY26.
EBITDA for Q2FY27 increased by 22.3% to ₹96.0 crore, while Profit After Tax (PAT) grew by 15.3% to ₹60.3 crore. The company noted that PAT and PAT Margins were lower due to increased depreciation and amortization charges from newly commissioned facilities and brand acquisitions, with revenue contributions expected to build up in upcoming quarters.
CORONA highlighted its strong performance in outperforming the Indian Pharmaceutical Market (IPM) growth, with a volume growth 2x higher than IPM and pricing 1.5x higher. The company's chronic and semi-chronic business segments contributed 71.2% to Q2FY27 revenue, showing a growth approximately 350 basis points higher than the company's overall growth. Furthermore, CORONA received Good Manufacturing Practice (GMP) certification from Brazil's ANVISA for its manufacturing facility in Ahmedabad, enhancing its global quality standards.
Mr. Nirav K. Mehta, Managing Director & CEO, commented, "We are pleased to announce another quarter of strong, consistent growth. Revenue grew 22.2% year-on-year in Q2FY27 and 22% in H1FY27, ahead of our stated guidance. Our domestic business grew at 22.9%, well ahead of the Indian Pharmaceutical Market (IPM) growth of 12%, and our chronic portfolio grew at nearly twice the rate of its market segment. This outperformance reflects our disciplined execution and consistent focus on our long-term strategy. We remain committed to strengthening our core therapies, building powerful brands, driving operational excellence and investing in capabilities that will support our future growth."
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.